SCHEMBL804193

SCHEMBL804193

O=C(O)c1ccc2c(C3CCCCC3)c3n(c2c1)CCN(CC(=O)N1CCOCC1)c1cc(Cl)ccc1-3

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 1/20 0.42
MMP12 P39900 1/20 0.42
NR1I2 O75469 1/20 0.40
F10 P00742 2/20 0.39
SCN9A Q15858 2/20 0.38
KDM4E B2RXH2 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KMT2A Q03164 1/20 0.35
ALDH1A1 P00352 4/20 0.34
TP53 P04637 2/20 0.34
MAPT P10636 2/20 0.34
RAB9A P51151 1/20 0.34
DPP4 P27487 1/20 0.34
DPP8 Q6V1X1 1/20 0.34
DPP9 Q86TI2 1/20 0.34
LMNA P02545 2/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
CASP3 P42574 1/20 0.33
SENP7 Q9BQF6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10283563 0.94 PRKCA (0.43) PRKCAMMP12F10SCN9AKMT2A
SCHEMBL12427679 0.91 PRKCA (0.42) PRKCAMMP12NR1I2SCN9ASMN1; SMN2
SCHEMBL10283491 0.91 PRKCA (0.44) PRKCAMMP12NR1I2SCN9ASMN1; SMN2
SCHEMBL10283262 0.90 PRKCA (0.48) PRKCAMMP12NR1I2SCN9AKDM4E
SCHEMBL12427625 0.89 PRKCA (0.42) PRKCAMMP12NR1I2SCN9AKDM4E
SCHEMBL12427629 0.89 PRKCA (0.43) PRKCAMMP12NR1I2SCN9ASMN1; SMN2
SCHEMBL12428861 0.88 PRKCA (0.43) PRKCAMMP12NR1I2SCN9AKDM4E
SCHEMBL10283493 0.88 PRKCA (0.43) PRKCAMMP12NR1I2SCN9AKDM4E
SCHEMBL803809 0.87 PRKCA (0.46) PRKCAMMP12NR1I2SCN9AKDM4E
SCHEMBL12428396 0.87 PRKCA (0.42) PRKCAMMP12NR1I2SCN9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed
EP-2206715-A1 Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor Japan Tobacco, Inc. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 PRKCA 2404/4885MMP12 1013/4885NR1I2 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.